Non-alcoholic fatty liver disease (NAFLD) with its two clinically different entities [non-alcoholic fatty liver disease (NAFL) and non-alcoholic steatohepatitis (NASH)] is a condition affecting an increasing number of people worldwide, predominantly diagnosed with non-invasive imaging techniques. Serological testing can be subdivided into three groups based on the stage of NAFLD and includes several tests: SteatoTest, NAFLD fibrosis score and ultrasonographic fatty liver indicator. Cytokeratin-18 is the single serologic test most studied so far regarding the diagnosis of NASH. Non-invasive imaging techniques include ultrasonography as the first frontier in the diagnostic algorithm, transient elastography (FibroScan) and acoustic radiation force impulse (ARFI) elastography as important tools used to determine the extent of the liver stiffness, and computed tomography (CT)/magnetic resonance imaging (MRI). However, liver biopsy still remains the gold standard for the diagnosis and classification standards of NAFLD, though this procedure should only be used when there is lack of more beneficial alternatives, due to its invasiveness and potential risks. It is important to say that patients have to be evaluated periodically and efficiently assessed in order to determine treatment results and lifestyle changes that have to be made to manage hepatic steatosis and other further complications.
KeywordsNon-alcoholic fatty liver Steatohepatitis Serological testing Non-invasive imaging techniques Liver biopsy
- 8.Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–609.CrossRefPubMedGoogle Scholar
- 16.Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard VJ, Senni-Buratti M, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther. 2010;32:1315–22.CrossRefPubMedGoogle Scholar
- 30.Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMedGoogle Scholar